Institute for Neurodegenerative Disorders

New Haven, Connecticut 06510

3 studies enrolling now · 73 studies all time

What they study most

Alzheimer Disease, Alzheimer's Disease, Alzheimers Disease, Alzheimer´s Disease, Autistic Spectrum Disorders, Behavioral Variant Frontotemporal Dementia, Depression, Early Alzheimer's Disease, Fragile X Syndrome, Healthy, Healthy Controls, Huntington Disease

Studies at this site

• A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease — Recruiting now
• PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort — Recruiting now
• Early Longitudinal Imaging in the Parkinson's Progressive Marker Initiative (PPMI) Using (18F)AV-133 (PPMI AV-133 Prodromal Imaging) — Recruiting now
• A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease — Running, not enrolling
• A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease — Completed
• A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1) — Completed
• A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease — Running, not enrolling
• A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) — Running, not enrolling
• A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4) — Completed
• Early Longitudinal Imaging in Parkinson's Progression Markers Initiative Using [¹⁸F] AV-133 and DaTscan™ — Running, not enrolling
• A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease — Completed
• Prospective Huntington At Risk Observational Study — Completed
• Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression — Completed
• Open-Label Study of Leuco-methylthioninium Bis(Hydromethanesulfonate) (LMTM) in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD) — Stopped early
• PPMI Tau PET Imaging — Completed
• Assessing Imaging as a Tool in Monitoring and Predicting the Progression of Parkinson Disease — Completed
• A Study Evaluating Potential Screening Tools for Detecting Parkinson Disease — Status unconfirmed
• Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance — Stopped early
• 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease — Stopped early
• Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients — Completed
• A Study of the Effects of Multiple Doses of LY3372689 on the Brain in Healthy Participants — Completed
• A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD). — Stopped early
• An Open-Label Crenezumab Study in Participants With Alzheimer's Disease — Stopped early
• A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia — Stopped early
• An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease — Stopped early
• A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia — Stopped early
• Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo — Stopped early
• Evaluation of [18F] PBR06 and PET as a Marker of Inflammation in Subjects With Neurological Conditions — Stopped early
• Assessment of the Effect of Sertaline on the Specific Binding of 123-I MZINT in Healthy Subjects — Stopped early
• The Study of the Impact of Disclosing Imaging Study Information to Trial Participants — Completed
• Evaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With PD or AD and in Healthy Subjects — Stopped early
• Evaluation of [123I] MNI-330 and SPECT as a Marker of Beta-amyloid Protein Deposition — Stopped early
• Brain Imaging Study in Subjects With Alzheimer Disease in Comparison to Healthy Subjects — Stopped early
• Single Photon Emission Computed Tomography (SPECT) Imaging Study to Develop a Biomarker for Alzheimer's Disease — Stopped early
• A Study of the Sense of Smell in Relatives of Parkinson's Disease Patients — Completed
• Evaluation of [123I] MNI-187 and SPECT in Patients With Alzheimers Disease in Comparison to Healthy Subjects — Completed
• Evaluation of [123I] AV51 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects — Completed
• Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease — Completed
• Systemic Synuclein Sampling Study (S4) — Completed
• Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in PD, HD and Healthy Subjects. — Completed
• A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions — Completed
• Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease — Completed
• Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients — Stopped early
• Study of Individuals With Parkinson's Symptoms But in Whom There is Diagnostic Uncertainty — Completed
• Safety of Urate Elevation in Parkinson's Disease — Completed
• Development of Imaging, Clinical and Biochemical Bio-Markers for Parkinson's Disease — Completed
• Imaging and Genetic Biomarkers of Parkinson Disease (PD) Onset and Progression in High-risk Families — Completed
• Evaluation of 5-[123I]-A-85380 and SPECT Imaging in Individuals With Parkinsons Disease — Completed
• Evaluation of 123-I Iodobenzovesamicol (IBVM) and SPECT Imaging of Healthy Subjects and Patients With Alzheimer Disease — Completed
• A Study of Brain Imaging With Nuclear Medicine Technology in Individuals With and at Risk for Parkinson's Disease — Completed